Press Release: Dupixent approved in the US as the first-ever ... - Sanofi
WEB2 days ago · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEB2 days ago · The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies...
Sanofi and Regeneron Biologic Drug Dupixent Notches a New …
WEB15 hours ago · The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary...
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB2 days ago · Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s count of U.S. indications up...
Sanofi/Regeneron’s Dupixent set to dominate COPD biologics …
WEB1 day ago · The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 monoclonal antibody, Dupixent, for the US market.
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEB2 days ago · Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD. Drug is cleared for 300,000 U.S. patients with a form of the lung disease driven by eosinophils. Wikimedia Commons. By...
Regeneron, Sanofi Get FDA OK of Dupixent for COPD — Update
WEB1 day ago · Regeneron Pharmaceuticals and Sanofi have won Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent in treatment of chronic obstructive pulmonary...
Sanofi US News
WEBMay 20, 2024 · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through the investigation of two potentially first-in-class biologics, Dupixent and itepekimab.
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's …
WEB2 days ago · (Reuters) -The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the...
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's …
WEB2 days ago · The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies...